Literature DB >> 27164936

Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer.

Roman Samsonov1,2, Vladimir Burdakov3,4, Tatiana Shtam3,4, Zamira Radzhabovа2, Dmitry Vasilyev2, Evgenia Tsyrlina2, Sergey Titov5, Michail Ivanov5, Lev Berstein2, Michael Filatov3,4, Nikolay Kolesnikov5, Hava Gil-Henn6, Anastasia Malek7,8,9.   

Abstract

Thyroid cancer (TC) is the most common endocrine malignancy and its incidence has increased over the last few decades. As has been revealed by a number of studies, TC tissue's micro-RNA (miRNA) profile may reflect histological features and the clinical behavior of tumor. However, alteration of the miRNA profile of plasma exosomes associated with TC development has to date not been explored. We isolated exosomes from plasma and assayed their characteristics using laser diffraction particle size analysis, atomic force microscopy, and western blotting. Next, we profiled cancer-associated miRNAs in plasma exosomes obtained from papillary TC patients, before and after surgical removal of the tumor. The diagnostic value of selected miRNAs was evaluated in a large cohort of patients displaying different statuses of thyroid nodule disease. MiRNA assessment was performed by RT-qPCR. In total, 60 patients with different types of thyroid nodal pathology were included in the study. Our results revealed that the development of papillary TC is associated with specific changes in exosomal miRNA profiles; this phenomenon can be used for differential diagnostics. MiRNA-31 was found to be over-represented in the plasma exosomes of patients with papillary TC vs. benign tumors, while miRNA-21 helped to distinguish between benign tumors and follicular TC. MiRNA-21 and MiRNA-181a-5p were found to be expressed reciprocally in the exosomes of patients with papillary and follicular TC, and their comparative assessment may help to distinguish between these types of TC with 100 % sensitivity and 77 % specificity.

Entities:  

Keywords:  Diagnostics; Exosomes; MicroRNA; Thyroid cancer

Mesh:

Substances:

Year:  2016        PMID: 27164936     DOI: 10.1007/s13277-016-5065-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  46 in total

1.  MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.

Authors:  Patrizia Agretti; Eleonora Ferrarini; Teresa Rago; Antonio Candelieri; Giuseppina De Marco; Antonio Dimida; Filippo Niccolai; Angelo Molinaro; Giancarlo Di Coscio; Aldo Pinchera; Paolo Vitti; Massimo Tonacchera
Journal:  Eur J Endocrinol       Date:  2012-06-22       Impact factor: 6.664

2.  Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222.

Authors:  James C Lee; Jing-Ting Zhao; Justin Gundara; Jonathan Serpell; Leon A Bach; Stan Sidhu
Journal:  J Surg Res       Date:  2015-02-19       Impact factor: 2.192

3.  Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.

Authors:  Shuang Yu; Yuanyuan Liu; Jingsong Wang; Zhuming Guo; Quan Zhang; Fengyan Yu; Yunjian Zhang; Kai Huang; Yanbing Li; Erwei Song; Xi-long Zheng; Haipeng Xiao
Journal:  J Clin Endocrinol Metab       Date:  2012-04-03       Impact factor: 5.958

4.  Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples.

Authors:  Yang Zhang; Qi Zhong; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2014-06-19

Review 5.  The Role of Exosomes in Breast Cancer.

Authors:  Michelle C Lowry; William M Gallagher; Lorraine O'Driscoll
Journal:  Clin Chem       Date:  2015-10-14       Impact factor: 8.327

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs.

Authors:  Wei-Xian Chen; Yan-Qin Cai; Meng-Meng Lv; Lin Chen; Shan-Liang Zhong; Teng-Fei Ma; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Tumour Biol       Date:  2014-06-27

8.  MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.

Authors:  James C Lee; Jing Ting Zhao; Roderick J Clifton-Bligh; Anthony Gill; Justin S Gundara; Julian C Ip; Anthony Glover; Mark S Sywak; Leigh W Delbridge; Bruce G Robinson; Stanley B Sidhu
Journal:  Cancer       Date:  2013-10-28       Impact factor: 6.860

9.  Absolute quantification of cell-free microRNAs in cancer patients.

Authors:  Manuela Ferracin; Laura Lupini; Irene Salamon; Elena Saccenti; Maria Vittoria Zanzi; Andrea Rocchi; Lucia Da Ros; Barbara Zagatti; Gentian Musa; Cristian Bassi; Alessandra Mangolini; Giorgio Cavallesco; Antonio Frassoldati; Stefano Volpato; Paolo Carcoforo; Alan B Hollingsworth; Massimo Negrini
Journal:  Oncotarget       Date:  2015-06-10

Review 10.  The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research.

Authors:  Yu Fujita; Kazuyoshi Kuwano; Takahiro Ochiya; Fumitaka Takeshita
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

View more
  34 in total

1.  miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.

Authors:  Chuanshan Zang; Jian Sun; Wenyi Liu; Chunqin Chu; Liwei Jiang; Ruifeng Ge
Journal:  Hum Cell       Date:  2019-06-03       Impact factor: 4.174

2.  MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4.

Authors:  Xiaofeng Xu; Feng Gao; Jianjiang Wang; Lan Tao; Jinsong Ye; Li Ding; Wei Ji; Xing Chen
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.

Authors:  Tara Jarboe; Neha Y Tuli; Sanjukta Chakraborty; Rachana R Maniyar; Nicole DeSouza; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.

Authors:  Sanjukta Chakraborty; Michelle Carnazza; Tara Jarboe; Nicole DeSouza; Xiu-Min Li; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner.

Authors:  Yu-Min Wang; Michael Patrick Trinh; Yongzan Zheng; Kaizhu Guo; Luis A Jimenez; Wenwan Zhong
Journal:  Trends Analyt Chem       Date:  2019-07-05       Impact factor: 12.296

6.  MicroRNA‑21 contributes to renal cell carcinoma cell invasiveness and angiogenesis via the PDCD4/c‑Jun (AP‑1) signalling pathway.

Authors:  Bo Fan; Yiying Jin; Hongshuo Zhang; Rui Zhao; Man Sun; Mengfan Sun; Xiaoying Yuan; Wei Wang; Xiaogang Wang; Zhiqi Chen; Wankai Liu; Na Yu; Qun Wang; Tingjiao Liu; Xiancheng Li
Journal:  Int J Oncol       Date:  2019-12-02       Impact factor: 5.650

7.  RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients.

Authors:  Yi-Huan Luo; Liang Liang; Rong-Quan He; Dong-Yue Wen; Guo-Fei Deng; Hong Yang; Yun He; Wei Ma; Xiao-Yong Cai; Jun-Qiang Chen; Gang Chen
Journal:  Oncotarget       Date:  2017-05-26

8.  The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer.

Authors:  Dong Ke; Hanwei Li; Yi Zhang; Yinghong An; Hanjiang Fu; Xuedong Fang; Xiaofei Zheng
Journal:  Oncotarget       Date:  2017-03-28

9.  Differentially expressed host long intergenic noncoding RNA and mRNA in HIV-1 and HIV-2 infection.

Authors:  Santanu Biswas; Mohan Haleyurgirisetty; Viswanath Ragupathy; Xue Wang; Sherwin Lee; Indira Hewlett; Krishnakumar Devadas
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

Review 10.  Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.

Authors:  Hao Wang; Ran Peng; Junjie Wang; Zelian Qin; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2018-04-23       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.